Hutchmed China Limited (HCM) Return on Assets ROA from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, Average High and Low, Fundamental Ratios from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Hutchmed china Limited  (NASDAQ: HCM)


Hutchmed China Limited's ROA from the fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Hutchmed China Limited's ROA in the fourth quarter of 2025?
Hutchmed china Limited achieved a return on average assets (ROA) of 24.32 % in its fourth quarter of 2025, this is above HCM's average return on assets of -7.29%.
Hutchmed China Limited assets over the 12 months ending in its fourth quarter of 2025 are valued at $1,882 million

ROA has improved compared to 2.18% in the third quarter of 2025, due to net income growth.

However, within the Healthcare sector 41 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 179.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Total Assets Change 32.79 % 38.26 % 66.38 % 38.26 % 35.07 %
Y / Y Net Income Change 1099.19 % - - - -62.24 %
Net Income (TTM) in million 458 38 38 38 38
Return On Assets (TTM) 24.32 % 2.18 % 2.35 % 2.64 % 2.89 %
HCM's Total Ranking # 179 # # # # 1869
Total Assets (TTM) in million 2,174 1,764 1,825 1,764 1,637
Seq. Total Assets Change 23.26 % -3.34 % 3.45 % 7.74 % 28.33 %
Seq. Net Income Change - - - - -

HCM's 5 Years Annual ROA >> Back to HCM Management Effectiveness >> Compare HCM ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 19
Sector # 42
Overall # 176

Return On Assets Statistics
High Average Low
26.11 %
-7.29 %
-35.01 %
(Dec 31 2025)   (Dec 31 2022)



  News about Hutchmed china Limited Return on Assets ROA

HUTCHMEDs ORPATHYS Approval: A Game-Changer for NSCLC Treatment Amidst Financial Resurgence

ArticleIn a defining moment for lung cancer treatment in China, HUTCHMED (China) Limited has secured full approval from the National Medical Products Administration (NMPA) for its groundbreaking drug ORPATHYS (savolitinib). This approval specifically targets patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who possess MET Exon 14 alterations. Notably, the indication has now expanded to include treatment-naïve patients, marking a significant milestone in the fight against this challenging disease.The news comes at a pivotal time for HUTCHMED, as the company reports a notable financial turnaround in its fourth quarter of 2023. The return on assets (ROA) surged to an impressive 7.89%, a stark improvement from an average ROA of -18.89% observed previously. This recovery reflects strategic advancements in its portfolio and a positive shift toward profitability, particularly given that the company s ROA was at a concerning -29.57% in Q3 2023. Such a turnaround is particularly commendable when compared to the broader healthcare sector, wherein 92 other companies have registered higher returns during the same period.



Financial Statements
Hutchmed China Limited's Assets $ 2,174 million HCM's Balance sheet
Hutchmed China Limited's Income $ 458 million Quarterly HCM's Income Statement
HCM's Income by Division See HCM's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 34.1 % 35.88 % 24.11 % -27.75 % 62.76 %
Total Assets in million 2,174 1,621 1,193 961 1,331
Y / Y Net Income Change 1099.19 % -62.24 % - - -
Net Income in million 458 38 101 -360 -167
Annual Return On Assets 21.05 % 2.35 % 8.47 % -37.49 % -12.55 %

HCM's 5 Years Annual ROA >> Back to HCM Management Effectiveness >> Compare HCM ROA to its Competitors



Comment on HCM's ROA in the fiscal year ending 2025
In the fiscal year 2025 ROA improved to 21.05 % compared to prior year, due to annual net income growth of 1099.19 % to $457.73 million, while value of Hutchmed China Limited's overall assets grew just by 34.1 % to $2,174.18 million, compared to $2,174.18 a year before.


More Return On Assets Ratios
HCM's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
HCM's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for HCM's Competitors
Subscribers only: Roa for Hutchmed China Limited's Suppliers
Subscribers only: Return On Assets for HCM's Customers

You may also want to know
HCM's Roi HCM's Inventory Turnover Ratio HCM's Growth Rates HCM's Dividend Comparisons
HCM's Profitability Ratios HCM's Asset Turnover Ratio HCM's Dividend Growth
HCM's Roe HCM's Valuation Ratios HCM's Financial Strength Ratios HCM's Dividend Payout Ratio



Companies with similar Return On Assets at Dec 31 2025, within Healthcare Sector ROA
Sanuwave Health Inc   65.98 %
Exelixis Inc   61.66 %
Entera Bio Ltd   61.28 %
Biocryst Pharmaceuticals Inc   55.61 %
Check Cap Ltd  55.30 %
Advanced Biomed Inc.  53.63 %
Enlivex Therapeutics Ltd  53.10 %
Tg Therapeutics Inc   51.88 %
Aurinia Pharmaceuticals Inc   50.24 %
Pulmatrix Inc   48.84 %
Earth Science Tech Inc   45.81 %
Q32 Bio Inc   45.06 %
Coherus Oncology inc   42.39 %
Elite Pharmaceuticals Inc   41.21 %
Alpha Tau Medical Ltd  40.35 %
Galmed Pharmaceuticals Ltd   37.04 %
Dariohealth Corp   36.94 %
Abeona Therapeutics Inc   35.76 %
Novavax inc   35.32 %
Medinotec Inc   34.18 %
Zevra Therapeutics Inc   33.84 %
Oramed Pharmaceuticals Inc  33.67 %
Idexx Laboratories Inc  31.91 %
Acadia Pharmaceuticals Inc   29.77 %
Newgenivf Group Limited  29.73 %
Hutchmed china Limited  26.11 %
Petros Pharmaceuticals inc   26.04 %
Adma Biologics Inc   25.98 %
Theravance Biopharma inc   25.35 %
Ptc Therapeutics inc   25.21 %

Date modified: 2026-07-07T11:20:53+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.